Wockhardt Q1 net profit falls 94 percent on plant bans
MUMBAI (Reuters) - Generic drugmaker Wockhardt Ltd (WCKH.NS) on Tuesday said its quarterly net profit plunged 94 percent, as U.S. Food and Drug Administration bans on its manufacturing plants continued to take a toll.
Wockhardt's April-June net profit was 199.5 million rupees($3.26 million), compared with 3.23 billion rupees a year earlier.
Net sales slumped 27 percent to 9.91 billion rupees.
The United States is Wockhardt's biggest market and the FDA has banned the import of generic drugs from two of the company's plants in India, citing quality lapses in the manufacturing process.
In May, the company said the FDA had also expressed concerns over production processes at its Chicago-based Morton Grove Pharmaceuticals unit, which accounts for more than 50 percent of Wockhardt's sales in the United States.
Wockhardt shares fell 5 percent to 674 rupees by 0627 GMT on Nifty that was up 0.54 percent.
($1 = 61.1700 Indian rupees)
(Reporting by Zeba Siddiqui in Mumbai; Editing by Anupama Dwivedi)
- Tweet this
- Share this
- Digg this
- Microsoft names next operating system 'Windows 10'
- Exclusive - India set to run out of critical free drug for HIV/AIDS programme
- Column: Why work with Modi? It’s the economy, stupid
- Obama, Modi work to deepen improving U.S.-India ties
- Hong Kong democracy protesters and officials mark uneasy National Day
India could run out of a critical medicine in its free HIV/AIDS drugs programme in three weeks due to bureaucratic bungling, a senior government official said, leaving more than 150,000 sufferers without life-saving drugs for about a month. Full Article